Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.
The sustenance of most solid tumors including head and neck cancers (HNCs) is strongly dependent on the presence of a functioning vascular network. In this study, we examined the acute effects of a tumor vascular disrupting agent (VDA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404), in an orthotopic model of human HNC. Noninvasive magnetic resonance imaging (MRI) was used to monitor the vascular response of orthotopic FaDu xenografts to VDA therapy. Untreated tumors showed a marked but heterogeneous pattern of enhancement after contrast agent injection on serial T1-weighted (T1W) MR images. After VDA treatment, T2W and T1W MRI revealed evidence of hemorrhaging and lack of functioning vessels (enhancement) within the tumor. Quantitative estimates of relative vascular volume also showed a significant (P < .01) reduction in DMXAA-treated tumors 24 hours after therapy compared with untreated controls. Histology and immunostaining of untreated orthotopic FaDu tumors revealed poorly differentiated squamous cell carcinoma histology with distinctly visible CD31(+) endothelial cells. In sharp contrast, minimal CD31 staining with irregular endothelial fragments and faint outlines of blood vessels were seen in DMXAA-treated tumor sections. CD31 immunostaining and histology also highlighted the selectivity of vascular damage and tissue necrosis after VDA therapy with no evidence of toxicity observed in normal salivary gland, heart, liver, and skeletal muscle tissues. Together, our results demonstrate a potent and selective vascular disruptive activity of DMXAA in an orthotopic HNC model. Further evaluation into its antitumor effects alone and in combination with other agents is warranted.
Seshadri
Mukund
M
Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Toth
Karoly
K
Cancer Metastasis Rev. 1998-1999;17(3):279-84
10352881
Cancer. 1972 Jan;29(1):117-21
4332311
Nat Rev Cancer. 2005 Jun;5(6):423-35
15928673
Neoplasia. 2006 Jul;8(7):534-42
16867215
J Magn Reson Imaging. 1997 Jan-Feb;7(1):68-74
9039595
Head Neck. 2005 Sep;27(9):771-84
15920746
Ann Otol Rhinol Laryngol. 1993 Mar;102(3 Pt 1):215-21
7681273
Photochem Photobiol. 2009 Jan-Feb;85(1):50-6
18643909
Clin Cancer Res. 2008 Apr 1;14(7):2102-10
18381951
Cell. 2000 Jan 7;100(1):57-70
10647931
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1198-207
18954713
Abdom Imaging. 2005 May-Jun;30(3):324-41
15688112
Br J Cancer. 2008 Dec 16;99(12):2006-12
19078952
J Clin Oncol. 2006 Jul 10;24(20):3293-8
16829653
Laryngoscope. 2006 Sep;116(9):1636-41
16954995
Clin Cancer Res. 2003 Jan;9(1):355-62
12538488
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Natl Cancer Inst. 2001 Jul 18;93(14):1040-1
11459857
Lancet Oncol. 2003 Mar;4(3):141-8
12623359
Invest Radiol. 1987 Aug;22(8):665-71
3667174
J Clin Oncol. 2006 Mar 1;24(7):1023-5
16505419
Anticancer Res. 2002 May-Jun;22(3):1755-8
12168864
Head Neck. 1996 Jul-Aug;18(4):343-6
8780945